JP2008538919A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008538919A5 JP2008538919A5 JP2008508906A JP2008508906A JP2008538919A5 JP 2008538919 A5 JP2008538919 A5 JP 2008538919A5 JP 2008508906 A JP2008508906 A JP 2008508906A JP 2008508906 A JP2008508906 A JP 2008508906A JP 2008538919 A5 JP2008538919 A5 JP 2008538919A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- antigen
- human
- binding
- binding portion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000427 antigen Substances 0.000 claims 29
- 108091007433 antigens Proteins 0.000 claims 29
- 102000036639 antigens Human genes 0.000 claims 29
- 108010068617 neonatal Fc receptor Proteins 0.000 claims 18
- 239000003112 inhibitor Substances 0.000 claims 10
- 238000000034 method Methods 0.000 claims 10
- 102000008100 Human Serum Albumin Human genes 0.000 claims 9
- 108091006905 Human Serum Albumin Proteins 0.000 claims 9
- 108090000765 processed proteins & peptides Proteins 0.000 claims 4
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 claims 3
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 claims 3
- 210000004408 hybridoma Anatomy 0.000 claims 3
- 229920001184 polypeptide Polymers 0.000 claims 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims 3
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 239000002202 Polyethylene glycol Substances 0.000 claims 2
- 229960001438 immunostimulant agent Drugs 0.000 claims 2
- 230000003308 immunostimulating effect Effects 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 2
- 229920001223 polyethylene glycol Polymers 0.000 claims 2
- 230000002285 radioactive effect Effects 0.000 claims 2
- 102000009027 Albumins Human genes 0.000 claims 1
- 108010088751 Albumins Proteins 0.000 claims 1
- 208000024869 Goodpasture syndrome Diseases 0.000 claims 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims 1
- 206010022491 Insulin resistant diabetes Diseases 0.000 claims 1
- 102000000588 Interleukin-2 Human genes 0.000 claims 1
- 108010002350 Interleukin-2 Proteins 0.000 claims 1
- 208000011200 Kawasaki disease Diseases 0.000 claims 1
- 241000699660 Mus musculus Species 0.000 claims 1
- 238000005481 NMR spectroscopy Methods 0.000 claims 1
- 108091034117 Oligonucleotide Proteins 0.000 claims 1
- 206010034277 Pemphigoid Diseases 0.000 claims 1
- 201000011152 Pemphigus Diseases 0.000 claims 1
- 241000721454 Pemphigus Species 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 1
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims 1
- 208000000594 bullous pemphigoid Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000007850 fluorescent dye Substances 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 108020001507 fusion proteins Proteins 0.000 claims 1
- 102000037865 fusion proteins Human genes 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 claims 1
- 229940121354 immunomodulator Drugs 0.000 claims 1
- 230000002584 immunomodulator Effects 0.000 claims 1
- 239000003022 immunostimulating agent Substances 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 229940079322 interferon Drugs 0.000 claims 1
- 230000003902 lesion Effects 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 208000001725 mucocutaneous lymph node syndrome Diseases 0.000 claims 1
- 206010028417 myasthenia gravis Diseases 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 201000001976 pemphigus vulgaris Diseases 0.000 claims 1
- 239000000816 peptidomimetic Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 150000003384 small molecules Chemical class 0.000 claims 1
- 239000003381 stabilizer Substances 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- 108700012359 toxins Proteins 0.000 claims 1
- 238000011830 transgenic mouse model Methods 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US67641205P | 2005-04-29 | 2005-04-29 | |
| PCT/US2006/014182 WO2006118772A2 (en) | 2005-04-29 | 2006-04-14 | Fcrn antibodies and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008538919A JP2008538919A (ja) | 2008-11-13 |
| JP2008538919A5 true JP2008538919A5 (enExample) | 2009-07-09 |
Family
ID=37105335
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008508906A Pending JP2008538919A (ja) | 2005-04-29 | 2006-04-14 | ＦｃＲｎ抗体およびその使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20100266530A1 (enExample) |
| EP (1) | EP1879920A2 (enExample) |
| JP (1) | JP2008538919A (enExample) |
| CA (1) | CA2606378A1 (enExample) |
| WO (1) | WO2006118772A2 (enExample) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2637929A1 (en) * | 2006-01-25 | 2007-08-02 | The Research Foundation Of State University Of New York | Anti-fcrn antibodies for treatement of auto/allo immune conditions |
| US20100166734A1 (en) * | 2006-12-20 | 2010-07-01 | Edward Dolk | Oral delivery of polypeptides |
| US10457719B2 (en) * | 2007-09-18 | 2019-10-29 | The Jackson Laboratory | Antibodies and FC fusion protein modifications with enhanced persistence or pharmacokinetic stability in vivo and methods of use thereof |
| CA3131470A1 (en) * | 2008-04-25 | 2009-10-29 | Takeda Pharmaceutical Company Limited | Fc receptor binding proteins |
| AU2015200004B2 (en) * | 2008-04-25 | 2017-02-16 | Bioverativ Therapeutics Inc. | Antibodies against fcrn and use thereof |
| KR101722961B1 (ko) | 2009-02-11 | 2017-04-04 | 알부메딕스 에이/에스 | 알부민 변이체 및 접합체 |
| WO2010138814A2 (en) * | 2009-05-29 | 2010-12-02 | The Brigham And Women's Hospital, Inc. | Disrupting fcrn-albumin interactions |
| MX2012004793A (es) | 2009-10-30 | 2012-07-20 | Novozymes Biopharma Dk As | Variantes de albumina. |
| JP5969458B2 (ja) | 2010-04-09 | 2016-08-17 | アルブミディクス アクティーゼルスカブ | アルブミン誘導体及び変異体 |
| CN103619353B (zh) | 2011-06-02 | 2016-01-06 | 戴埃克斯有限公司 | Fc受体结合蛋白 |
| US20140315817A1 (en) | 2011-11-18 | 2014-10-23 | Eleven Biotherapeutics, Inc. | Variant serum albumin with improved half-life and other properties |
| DK2825556T3 (en) | 2012-03-16 | 2018-04-16 | Albumedix As | albumin Variants |
| GB201208370D0 (en) | 2012-05-14 | 2012-06-27 | Ucb Pharma Sa | Antibodies |
| KR20150082422A (ko) | 2012-11-08 | 2015-07-15 | 노보자임스 바이오파마 디케이 에이/에스 | 알부민 변이체 |
| ZA201506407B (en) * | 2013-03-15 | 2018-11-28 | Affibody Ab | New polypeptides |
| CA2902657C (en) * | 2013-03-15 | 2022-05-10 | Affibody Ab | Fcrn binding polypeptides |
| GB201320066D0 (en) | 2013-11-13 | 2013-12-25 | Ucb Pharma Sa | Biological products |
| ES2909014T3 (es) * | 2013-11-26 | 2022-05-04 | Brigham & Womens Hospital Inc | Composiciones y métodos para modular una respuesta inmunitaria |
| JP6554473B2 (ja) * | 2013-12-24 | 2019-07-31 | アルゲン−エックス ビーブイビーエー | ＦｃＲｎアンタゴニスト及び使用方法 |
| EP3134733B1 (en) * | 2014-04-25 | 2020-10-14 | The Brigham and Women's Hospital, Inc. | Assay and method for treating subjects with immune-mediated diseases |
| CA2983794A1 (en) * | 2014-04-25 | 2015-10-29 | The Brigham And Women's Hospital, Inc. | Methods to manipulate alpha-fetoprotein (afp) |
| NZ737666A (en) | 2014-04-30 | 2018-10-26 | Hanall Biopharma Co Ltd | Antibody binding to fcrn for treating autoimmune diseases |
| US10336825B2 (en) | 2014-04-30 | 2019-07-02 | Hanall Biopharma Co., Ltd. | Antibody binding to FcRn for treating autoimmune diseases |
| US10323066B2 (en) | 2014-09-17 | 2019-06-18 | Affibody Ab | Neonatal Fc receptor binding dimer and methods of use |
| CA3022547A1 (en) * | 2015-05-12 | 2016-11-17 | Syntimmune, Inc. | Humanized affinity matured anti-fcrn antibodies |
| GB201508180D0 (en) | 2015-05-13 | 2015-06-24 | Ucb Biopharma Sprl | Antibodies |
| EP3337816B1 (en) | 2015-08-20 | 2024-02-14 | Albumedix Ltd | Albumin variants and conjugates |
| CN106957365B (zh) | 2016-01-11 | 2021-03-16 | 上海交通大学 | 一种单克隆抗体FnAb8及其应用 |
| GB201618424D0 (en) * | 2016-11-01 | 2016-12-14 | Argenix Bvba | Treatment of antibody mediated disease |
| KR20200096786A (ko) | 2017-12-08 | 2020-08-13 | 아르제넥스 비브이비에이 | 전신 중증 근무력증의 치료를 위한 FcRn 길항제의 용도 |
| US12202900B2 (en) | 2018-06-08 | 2025-01-21 | argenx BV | Compositions and methods for treating immune thrombocytopenia |
| MX2021004351A (es) | 2018-10-16 | 2021-05-31 | UCB Biopharma SRL | Metodo para el tratamiento de miastenia grave. |
| JP7565951B2 (ja) | 2019-06-07 | 2024-10-11 | アルジェニクス ビーブイ | 皮下投与に好適なＦｃＲｎインヒビターの医薬製剤 |
| CA3163172A1 (en) | 2020-01-08 | 2021-07-15 | Peter Verheesen | Methods for treating pemphigus disorders |
| CA3183153A1 (en) * | 2020-06-17 | 2021-12-23 | Christian HINDERER | Compositions and methods for treatment of gene therapy patients |
| WO2023016538A1 (en) * | 2021-08-13 | 2023-02-16 | Staidson (Beijing) Biopharmaceuticals Co., Ltd. | Antibodies specifically recognizing fcrn and uses thereof |
| WO2023198806A1 (en) * | 2022-04-13 | 2023-10-19 | Ose Immunotherapeutics | New class of molecules for selective clearance of antibody |
| KR20250018382A (ko) | 2022-05-30 | 2025-02-05 | 한올바이오파마주식회사 | 안정성이 향상된 항-FcRn 항체 또는 이의 항원 결합 단편 |
| CN119630697A (zh) | 2022-06-15 | 2025-03-14 | 阿根思有限公司 | Ph依赖性hsa结合分子及使用方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6030613A (en) * | 1995-01-17 | 2000-02-29 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of therapeutics |
| US6096871A (en) * | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| US6992234B2 (en) * | 2000-11-06 | 2006-01-31 | The Jackson Laboratory | FcRn-based therapeutics for the treatment of auto-immune disorders |
| JP2007501847A (ja) * | 2003-08-08 | 2007-02-01 | ザ リサーチ ファウンデイション オブ ステイト ユニバーシティー オブ ニューヨーク | 自己／同種免疫状態の治療用抗ＦｃＲｎ抗体 |
| US7662928B2 (en) * | 2003-08-08 | 2010-02-16 | The Research Foundation Of State University Of New York | Anti-FcRn antibodies for treatment of auto/allo immune conditions |
-
2006
- 2006-04-14 WO PCT/US2006/014182 patent/WO2006118772A2/en not_active Ceased
- 2006-04-14 EP EP06758353A patent/EP1879920A2/en not_active Withdrawn
- 2006-04-14 US US11/919,596 patent/US20100266530A1/en not_active Abandoned
- 2006-04-14 JP JP2008508906A patent/JP2008538919A/ja active Pending
- 2006-04-14 CA CA002606378A patent/CA2606378A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008538919A5 (enExample) | ||
| CN105980407B (zh) | 单克隆抗tk1抗体 | |
| ES2532410T3 (es) | Identificación de antígenos asociados a tumores para diagnóstico y terapia | |
| Leach et al. | Use of tissue cross-reactivity studies in the development of antibody-based biopharmaceuticals: history, experience, methodology, and future directions | |
| JP2014113150A5 (enExample) | ||
| JP2007526233A5 (enExample) | ||
| JP2009100745A5 (enExample) | ||
| JP2020534830A5 (enExample) | ||
| JP2019511201A5 (enExample) | ||
| RU2014120536A (ru) | Белки специфического связывания и их применения | |
| RU2012147960A (ru) | Trail r2-специфические мультимерные скаффолды | |
| JP2013506428A5 (enExample) | ||
| RU2009137784A (ru) | Человеческое опухолеспецифическое моноклональное антитело | |
| JP2020516603A5 (enExample) | ||
| JP2009541204A5 (enExample) | ||
| Kroenke et al. | Immunogenicity risk assessment for multi-specific therapeutics | |
| JP2011501946A5 (enExample) | ||
| JP2019512207A5 (enExample) | ||
| JP2014515600A5 (enExample) | ||
| RU2012127378A (ru) | Средства для лечения заболевания | |
| JP2013136530A (ja) | Ｉｌ−２８ｂの分析方法 | |
| JP6977105B2 (ja) | Ｉｇｆ−１ｒ抗体および癌の診断のためのその使用 | |
| JP2017536821A5 (enExample) | ||
| JP5821198B2 (ja) | 抗ｉｌ２８ｂ抗体及びこれを用いたｉｌ２８ｂの測定方法 | |
| JP2008515388A5 (enExample) |